blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3062798

EP3062798 - MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  21.02.2025
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  03.04.2020
FormerGrant of patent is intended
Status updated on  11.03.2020
FormerExamination is in progress
Status updated on  01.03.2019
FormerGrant of patent is intended
Status updated on  14.01.2019
FormerExamination is in progress
Status updated on  14.12.2018
FormerGrant of patent is intended
Status updated on  31.07.2018
FormerExamination is in progress
Status updated on  02.06.2017
Most recent event   Tooltip21.02.2025Revocation of patentpublished on 26.03.2025  [2025/13]
21.02.2025New entry: Despatch of communication that patent is revoked 
Applicant(s)For all designated states
CureVac SE
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
[2023/01]
Former [2021/10]For all designated states
CureVac AG
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
Former [2016/36]For all designated states
CureVac AG
Paul-Ehrlich-Str. 15
72076 Tübingen / DE
Inventor(s)01 / SCHLAKE, Thomas
Gartenweg 1
79194 Gundelfingen / DE
02 / THESS, Andreas
Hindenburgstrasse 9
72127 Kusterdingen / DE
 [2016/36]
Representative(s)Graf von Stosch, Andreas, et al
Graf von Stosch
Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
[2016/36]
Application number, filing date14809289.331.10.2014
[2016/36]
WO2014EP02931
Priority number, dateWO2013EP0329301.11.2013         Original published format: PCT/EP2013/003293
[2016/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015062738
Date:07.05.2015
Language:EN
[2015/18]
Type: A1 Application with search report 
No.:EP3062798
Date:07.09.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 07.05.2015 takes the place of the publication of the European patent application.
[2016/36]
Type: B1 Patent specification 
No.:EP3062798
Date:06.05.2020
Language:EN
[2020/19]
Search report(s)International search report - published on:EP07.05.2015
ClassificationIPC:A61K31/7105, C12N15/117
[2016/36]
CPC:
A61K31/7105 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/36]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MODIFIZIERTE RNA MIT VERMINDERTEN IMMUNSTIMULIERENDEN EIGENSCHAFTEN[2016/36]
English:MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES[2016/36]
French:ARN MODIFIÉ À PROPRIÉTÉS IMMUNOSTIMULANTES RÉDUITES[2016/36]
Entry into regional phase11.04.2016National basic fee paid 
11.04.2016Designation fee(s) paid 
11.04.2016Examination fee paid 
Examination procedure11.04.2016Amendment by applicant (claims and/or description)
11.04.2016Examination requested  [2016/36]
02.06.2017Despatch of a communication from the examining division (Time limit: M04)
12.10.2017Reply to a communication from the examining division
26.01.2018Despatch of a communication from the examining division (Time limit: M04)
05.06.2018Reply to a communication from the examining division
01.08.2018Communication of intention to grant the patent
11.12.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.01.2019Communication of intention to grant the patent
08.02.2019Observations by third parties
18.02.2019Fee for grant paid
18.02.2019Fee for publishing/printing paid
28.02.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.03.2019Despatch of a communication from the examining division (Time limit: M06)
13.09.2019Reply to a communication from the examining division
02.01.2020Observations by third parties
21.01.2020Despatch of a communication from the examining division (Time limit: M04)
03.02.2020Reply to a communication from the examining division
12.03.2020Communication of intention to grant the patent
23.03.2020Receipt of the translation of the claim(s)
Divisional application(s)EP19157866.5  / EP3542802
Opposition(s)Opponent(s)01  05.02.2021  09.02.2021  ADMISSIBLE
Weickmann & Weickmann PartmbB
P.O. Box 860 820
81635 München / DE
 02  08.02.2021  10.02.2021  ADMISSIBLE
Weinzierl, Gerhard
Schiweck Weinzierl Koch
Patentanwälte Partnerschaft mbB
Ganghoferstraße 68B
80339 München / DE
Opponent's representative
Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
 [2021/11]
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
25.02.2021Invitation to proprietor to file observations on the notice of opposition
07.07.2021Reply of patent proprietor to notice(s) of opposition
07.10.2022Date of oral proceedings
10.11.2022Despatch of minutes of oral proceedings
10.11.2022Date of despatch of rejection of opposition
17.02.2025Legal effect of revocation of patent [2025/13]
17.02.2025Despatch of communication that the patent will be revoked
Appeal following opposition18.01.2023Appeal received No.  T2643/22
18.01.2023Payment of appeal fee
20.03.2023Statement of grounds filed
14.02.2025Result of appeal procedure: revocation of the patent
17.02.2025Despatch of the decision of the Board of Appeal
21.12.2022Appeal received No.  T2643/22
21.12.2022Payment of appeal fee
20.03.2023Statement of grounds filed
14.02.2025Result of appeal procedure: revocation of the patent
17.02.2025Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
08.08.2016Renewal fee patent year 03
04.09.2017Renewal fee patent year 04
24.08.2018Renewal fee patent year 05
04.09.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU31.10.2014
AL06.05.2020
AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
MK06.05.2020
MT06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
TR06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
BE31.10.2020
IE31.10.2020
LU31.10.2020
[2022/32]
Former [2022/27]HU31.10.2014
AL06.05.2020
AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
MT06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
TR06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
BE31.10.2020
IE31.10.2020
LU31.10.2020
Former [2021/46]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
BE31.10.2020
IE31.10.2020
LU31.10.2020
Former [2021/36]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
BE31.10.2020
LU31.10.2020
Former [2021/31]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
LU31.10.2020
Former [2021/24]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/10]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/09]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/08]AL06.05.2020
DK06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/04]AL06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
RS06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/01]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/51]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
SE06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/50]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
SE06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/48]FI06.05.2020
LT06.05.2020
SE06.05.2020
NO06.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/47]LT06.05.2020
NO06.08.2020
IS06.09.2020
Former [2020/46]IS06.09.2020
Cited inInternational search[XD]WO02098443  (VON DER MUELBE FLORIAN [DE], et al) [XD] 12-16 * the whole document, in particular p.6-8 and claims *;
 [I]WO2006049777  (DARTMOUTH COLLEGE [US], et al) [I] 12-16 * the whole document, in particular SEQ ID NO: 1 *;
 [AD]WO2007024708  (UNIV PENNSYLVANIA [US], et al) [AD] 1-21;
 [X]WO2009127230  (CUREVAC GMBH [DE], et al) [X] 1-21 * the whole document, in particular p. 51-56 and claims *;
 [AD]  - KARIKO ET AL., CURR. OPIN. DRUG DISCOV DEVEL., (2007), vol. 10, no. 5, pages 523 - 32, XP009154595 [AD] 1-21
 [A]  - THOMAS SCHLAKE ET AL, "Developing mRNA-vaccine technologies", RNA BIOLOGY, (20121101), vol. 9, no. 11, doi:10.4161/rna.22269, ISSN 1547-6286, XP055126360 [A] 1-21

DOI:   http://dx.doi.org/10.4161/rna.22269
 [A]  - KARL-JOSEF KALLEN ET AL, "A novel, disruptive vaccination technology: Self-adjuvanted RNActive vaccines", HUMAN VACCINES & IMMUNOTHERAPEUTICS, (20131001), vol. 9, no. 10, doi:10.4161/hv.25181, ISSN 2164-5515, pages 16 - 29, XP055126357 [A] 1-21

DOI:   http://dx.doi.org/10.4161/hv.25181
 [T]  - K.-J. KALLEN ET AL, "A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs", THERAPEUTIC ADVANCES IN VACCINES, (20131106), vol. 2, no. 1, doi:10.1177/2051013613508729, ISSN 2051-0136, pages 10 - 31, XP055126338

DOI:   http://dx.doi.org/10.1177/2051013613508729
by applicantWO02098443
 WO2007024708
 WO2008077592
 WO2011012316
 WO2011071931
 WO2011130624
 US2011275793
 WO2013052523
    - FOTIN-MLECZEK ET AL., J. IMMUNOTHER., (2011), vol. 34, no. 1, pages 1 - 15
    - SCHLAKE ET AL., RNA BIOL., (2012), vol. 9, no. 11, pages 1319 - 30
    - KARIKO ET AL., MOL. THER., (2012), vol. 20, no. 5, pages 948 - 53
    - KORMANN ET AL., NAT. BIOTECHNOL., (2011), vol. 29, no. 2, pages 154 - 7
    - DESMET ET AL., NAT. REV. IMMUNOL., (2012), vol. 12, no. 7, pages 479 - 91
    - ZÜST ET AL., NAT. IMMUNOL., (2011), vol. 12, no. 2, pages 137 - 43
    - BROZ ET AL., NAT. REV. IMMUNOL., (2013), vol. 13, no. 8, pages 551 - 65
    - SHARP ET AL., VIROLOGY, (1999), vol. 257, no. 2, pages 303 - 13
    - KARIKO ET AL., IMMUNITY, (2005), vol. 23, no. 2, pages 165 - 75
    - KARIKO ET AL., CURR. OPIN. DRUG DISCOV DEVEL., (2007), vol. 10, no. 5, pages 523 - 32
    - ANDERSON ET AL., NUCLEIC ACIDS RES., (2010), vol. 38, no. 17, pages 5884 - 92
    - ANDERSON ET AL., NUCLEIC ACIDS RES., (2011), vol. 39, no. 21, pages 9329 - 38
    - KARIKO ET AL., NUCLEIC ACIDS RES., (2011), vol. 39, no. 21, page E142
    - KARIKO ET AL., MOL. THER., vol. 20, no. 5, pages 948 - 53
    - KORMANN, NAT. BIOTECHNOL., (2011), vol. 29, no. 2, pages 154 - 7
    - WARREN ET AL., CELL STEM CELL, (2010), vol. 7, no. 5, pages 618 - 30
    - SHARP; LI, NUCLEIC ACIDS RES., (19870211), vol. 15, no. 3, pages 1281 - 95
    - RAMAZOTTI ET AL., IN SILICO BIOL., (2007), vol. 7, no. 4-5, pages 507 - 26
    - ROBBINS ET AL., OLIGONUCLEOTIDES, (2009), vol. 19, no. 2, pages 89 - 102
    - DUAN; JEFCOATE, J. MOL. ENDOCRINOL., (2007), vol. 38, no. 1-2, pages 159 - 79
    - KOZAK, MOL CELL BIOL., (198911), vol. 9, no. 11, pages 5073 - 80
    - HOLCIK ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 2410 - 2414
    - E.W. MARTIN, Remington's Pharmaceutical Sciences
    - GUIDELINES MEDICINAL PRODUCTS FOR HUMAN USE SAFETY, ENVIRONMENT AND INFORMATION EXCIPIENTS IN THE LABEL AND PACKAGE LEAFLET OF MEDICINAL PRODUCTS FOR HUMAN USE, (200307), vol. 3B
    - SELKOE, ANNU. REV. NEUROSCI., (1994), vol. 17, pages 489 - 517
    - CHESSLER ET AL., J. BIOL. CHEM., (1993), vol. 268, pages 18226 - 18233
    - MARQUARDT ET AL., EUR. J. CELL. BIOL., (1995), vol. 66, pages 268 - 273
    - BRADFORD ET AL., BIOCHEM. J., (1999), vol. 341, pages 193 - 201
    - KAUSHAL ET AL., BIOCHEMISTRY, (1994), vol. 33, pages 6121 - 8
    - KATO ET AL., BLOOD, (1992), vol. 79, pages 3212 - 8
    - ARBINI ET AL., BLOOD, (1996), vol. 87, pages 5085 - 94
    - HALABAN ET AL., PROC. NATL. ACAD. SCI. USA., (2000), vol. 97, pages 5889 - 94
    - KATSUMI ET AL., BLOOD, (1996), vol. 87, pages 4164 - 75
    - WALTER ET AL., AM J HUM GENET, (2001), vol. 69, pages 35 - 48
    - BEUTLER ET AL., The Metabolic and Molecular Bases of Inherited Disease, MCGRAW-HILL, pages 3635 - 3668
    - THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE, pages 3775 - 3810
    - The Metabolic and Molecular Bases of Inherited Disease, MCGRAW-HILL, (1995), pages 2529 - 2561
    - THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE, pages 3421 - 3452
    - THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE, pages 3389 - 3420
    - WEISMANN ET AL., SCIENCE, (1970), vol. 169, pages 72 - 74
    - The Metabolic and Molecular Bases of Inherited Disease, MCGRAW-HILL, pages 3589 - 3610
    - THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE, pages 3733 - 3774
    - DESNICK ET AL., The Metabolic and Molecular Bases of Inherited Disease, MCGRAW-HILL, (2001), pages 3733 - 3774
    - BRADY ET AL., N. ENGL. J. MED., (1967), vol. 276, pages 1163 - 1167
    - The Metabolic and Molecular Bases of Inherited Disease, MCGRAW-HILL, (2001), pages 3733 - 3774
    - NAKAO ET AL., N. ENGL. J. MED., (1995), vol. 333, pages 288 - 293
    - BISHOP ET AL., AM. J. HUM. GENET., (1985), vol. 37, page A144
    - CALHOUN ET AL., PROC. NATL. ACAD SCI. USA, (1985), vol. 82, pages 7364 - 7368
    - BISHOP ET AL., PROC. NATL. ACAD. SCI. USA, (1986), vol. 83, pages 4859 - 4863
    - TSUJI ET AL., BUR. J. BIOCHEM., (1987), vol. 165, pages 275 - 280
    - KORNREICH ET AL., NUCLEIC ACIDS RES., (1989), vol. 17, pages 3301 - 3302
    - ENG ET AL., AM. J. HUM. GENET., (1993), vol. 53, pages 1186 - 1197
    - ENG ET AL., MOL. MED., (1997), vol. 3, pages 174 - 182
    - DAVIES ET AL., BUR. J. HUM. GENET., (1996), vol. 4, pages 219 - 224
other   - GALIGER C. et al, "Assessment of Efficacy of Antifungals against Aspergillus fumigatus: Value of Real-Time Bioluminescence Imaging", Journal of Biological Chemistry, (20130711), vol. 57, no. 7, pages 3046 - 3059, XP055561132

DOI:   http://dx.doi.org/10.1128/AAC.01660-12
    - WEI et al., "The Stringency of Start Codon Selection in the Filamentous FungusNeurospora crassa", Journal of Biological Chemistry, (20130329), vol. 288, no. 13, pages 9549 - 9562, XP055561136

DOI:   http://dx.doi.org/10.1074/jbc.M112.447177
    - NGUMBELA et al., "Quantitative Effect of Suboptimal Codon Usage on Translational Efficiency of mRNA Encoding HIV-1 gag in Intact T Cells", PLoS One, (20080604), vol. 3, no. 6, page e2356, XP055661944

DOI:   http://dx.doi.org/10.1371/journal.pone.0002356
OppositionWO02098443
 WO2009127230
 WO2015062738
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.